A Lancet study found that low-dose peanut oral immunotherapy safely desensitised 82.5% of allergic preschool children. Researchers said the gradual treatment approach improved peanut tolerance while reducing severe side effects commonly linked to immunotherapy. Early intervention may help lower life-threatening allergic reactions and reshape future treatment strategies.